Effects of nicotinamide mononucleotide on older patients with diabetes and impaired physical performance: A prospective, placebo-controlled, double-blind study

This 24-week placebo-controlled double-blind study tested 250 mg/day NMN in older men with diabetes and impaired physical performance. Fourteen participants were analyzed.

NMN was reported as tolerable without severe adverse events, but the two main functional outcomes—grip strength and walking speed—did not significantly differ between groups. The exploratory outcomes also did not show statistically significant between-group differences.

Frailty prevalence and retinal-thickness measures showed borderline trends in the original report, but those results were not statistically confirmatory and should not be described as demonstrated benefits.

• NMN was tolerated without severe adverse events over 24 weeks.
• Grip-strength change did not significantly differ between NMN and placebo.
• Walking-speed change did not significantly differ between NMN and placebo.
• No exploratory endpoint showed a statistically significant between-group difference in the parent report.
• Frailty prevalence (p=0.066) and central retinal thickness (p=0.051) were non-significant trends, not confirmed treatment effects.

• Very small sample: 14 analyzed participants.
• Participants were older men with diabetes and impaired physical performance, limiting generalizability.
• Primary functional outcomes were null.
• Exploratory analyses were numerous and underpowered.
• Commercial Teijin/NOMON affiliations are present among the authors.